Pexidartinib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Pexidartinib Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Pexidartinib Hydrochloride can convert its Small molecule drug profile and CSF-1R x FLT3 x c-Kit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Pexidartinib Hydrochloride (query alias: Pexidartinib Hydrochloride) |
|---|---|
| Modality / target | Small molecule drug; CSF-1R x FLT3 x c-Kit; CSF-1R antagonists, FLT3 inhibitors, c-Kit inhibitors |
| Highest global status | Approved |
| Originator | Daiichi Sankyo Co., Ltd. |
| Active developers | Daiichi Sankyo Co., Ltd., Daiichi Sankyo, Inc., Daiichi Sankyo Korea Co., Ltd. |
The MCP disease footprint includes Giant Cell Tumor of Tendon Sheath, Testicular Germ Cell Tumor, Adenocarcinoma of Lung. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04526704 | Phase 4 | Completed | 32 | Number of Treatment-Free Participants at 12 Months In The Treatment-free/Re-treatment Cohort |
| NCT04488822 | Phase 3 | Active, not recruiting | 40 | Overall Response Rate (ORR) of Pexidartinib Based on RECIST 1.1 of Asian Participants With Symptomatic Tenosynovial Giant Cell Tumor (TGCT) at Week 25 |
| NCT04703322 | Phase 2 | Completed | 9 | Dose-limiting Toxicity (DLT) in Part 1 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor
Phase 3; n=40; evaluation: Positive. Reported fields: ORR(RECIST v1.1) = 22.5 % ( 10.8 - 38.5)
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
Phase 3; n=120; evaluation: Positive. Reported fields: ORR(Response per RECIST v1.1) = 60.4 % (95%CI, 50–70); ORR(Response per RECIST v1.1) = 61 % (95%CI, 48–72); ORR(Response per RECIST v1.1) = 0 % (95%CI, 0–6)
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Phase 1/2; n=39; evaluation: not stated. Reported fields: -; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Pexidartinib Hydrochloride addresses Giant Cell Tumor of Tendon Sheath, Testicular Germ Cell Tumor, Adenocarcinoma of Lung. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 51 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CSF-1R x FLT3 x c-Kit records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-12-22 | 上海海和生物与石药集团携手推进新药研发新篇章 | Phase 2 | Financial terms not disclosed |
| 2025-06-12 | Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions | Approved | Financial terms not disclosed |
| 2025-03-06 | 拜耳医药授予亿帆医药拜万戈和多吉美在中国的独家市场推广权益 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
